RxDoctor Payments Data

Federico Rodriguez Perez, MD

Hepatology · San Juan, PRNPI 1639143480

Payments from drug & device makers

$580,029in general payments, 2019–2025

Across 588 payments — averaging $986.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boehringer Ingelheim International GmbH$166K
  • Bausch Health US, LLC$122K
  • Gilead$76K
  • AbbVie$75K
  • Regeneron$56K
  • Intercept Pharmaceuticals, Inc.$35K
  • plus $50K from 9 others
$120,243in research payments, 2019–2025

Across 53 payments — averaging $2268.73 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Intercept Pharmaceuticals, Inc.$102K
  • Intercept Pharma Europe Ltd.$17K
  • Eli Lilly$1K

What the payments were for

  • Consulting fees$15,5308%
  • Speaking & faculty fees$164,84385%
  • Travel & lodging$4,9973%
  • Food & beverage$9,5375%
  • Education$200%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few hepatology providers in Puerto Ricoto place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$71,314
Medicare patients
173
Services billed
498

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OcalivaObeticholic Acid19$176,873
XifaxanRifaximin19$61,909
Ursodiol417$43,272
SuprepSodium, Potassium,mag Sulfates163$19,163
Dexlansoprazole DrDexlansoprazole68$16,325
LinzessLinaclotide26$16,164
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates189$14,638
Pantoprazole Sodium1,031$8,789
Entecavir58$7,564
DexilantDexlansoprazole16$7,341
Famotidine1,037$6,843
Mesalamine DrMesalamine18$5,582
Sucralfate99$5,444
CholestyramineCholestyramine (With Sugar)29$2,885
Naloxone Hcl225$2,674

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Intercept Pharmaceuticals, Inc.Ocaliva$34,655$176,87319 claims
AbbVieLinzess$74,701$16,16426 claims
Takeda Pharmaceuticals U.S.A., Inc.Dexilant$108$7,34116 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few hepatology providers in Puerto Ricoon file to place this against a meaningful peer group, so we don't.

Other hepatology in San Juan

Where these figures come from

Is this you, or does something look wrong? →